Review on Immunotherapy Strategies against Infectious and Noninfectious Diseases by Tesfay Sisay, Addis Beyene Addis
Journal of Health, Medicine and Nursing                                                                                                                                          www.iiste.org 
ISSN 2422-8419     An International Peer-reviewed Journal 
Vol.19, 2015 
 
77 
Review on Immunotherapy Strategies against Infectious and 
Noninfectious Diseases 
 
Addis Beyene Addis1      Tesfay Sisay2 
1 Animal production and Technology, PO Box 50, Adigrat University, Adigrat, Ethiopia 
2 Cellular ,molecular biology, PO Box 1176, Addis Ababa University, Addis Ababa, Ethiopia 
 
Abstract 
Immunotherapy, in its broadest sense, encompasses the treatment and prevention of a large number and variety 
of immunologic and non immunologic diseases. Immunization may be active, in which administration of antigen 
(usually a modified infectious agent or toxin) results in active production of immunity, or passive, in which 
administration of antibody containing serum or sensitized cells provides passive protection for the recipient. 
Several mechanisms to stimulate immune system of host through different types of cell or cell extract, such as 
cellular therapy, immunomodulators, and antibody therapy. The potential for prophylaxis and therapy for 
veterinary medicine and human medicine comprise the following: control of infectious disease, cancer therapy, 
specific treatment of autoimmune disease, immunomodulation of allergic disease. However, risks associated 
with immunotherapies, such as toxicity and hypersensitivity, also have been documented.  
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1. INTRODUCTION 
The living animal’s body contains all the components necessary to sustain life. It is warm, moist, and full of 
nutrients. As a result, animal tissues are extremely attractive to a vast array of microorganisms. This can be readily 
seen when animals die. It begins to smell and decay as microbial invasions occurs. The tissue of living, healthy 
animals are resistant to microbial invasions because of the presence within the body of a vast array of defense 
mechanisms. Indeed, the survival of an animal depends on the successful defense of the body against microbial 
invasions (Tizard, 1996).  
 The best way to prevent and remove infections is through the natural 'sterilizing' action of the immune 
response that combines elements of both innate and adaptive immunity toward off foreign pathogens without 
medical intervention. The immune system 'remembers' the cleared foreign antigens to speed up its response to 
re-infection. The immune system in most cancer patients can still completely destroy viruses and bacteria. The 
ferocity and specificity of this response can be witnessed in the way an inadequately suppressed immune system 
can completely destroy a large transplanted organ, while sparing one’s own (self) tissues. This destructive effect 
would be beneficial for cancer therapy if it could be directed at tumors (Matzinger, 2001). 
Immunotherapy is a form of biologic therapy or biotherapy. It is treatment that uses certain parts of the 
immune system to fight diseases. This can be done in a couple of ways either stimulating own immune system to 
work harder or smarter or giving  immune system components, such as man-made immune system proteins that 
triggers the body's immune system to recognize and respond to cancerous cells. Some forms of immunotherapy 
include interferons, vaccines, and monoclonal antibodies (Prehn et al., 1996).  
Therefore, the objectives of this paper are to review current immunotherapy strategies against infectious 
and noninfectious diseases and to forward appropriate recommendation on the applications and challenges of 
immunotherapy. 
 
2. IMMUNOTHERAPEUTIC STRATEGIES 
The development of immunotherapy technology is more recent. There are two main types of immunotherapy. 
Active immunotherapies stimulate body's own immune system to fight the disease. Passive immunotherapies do 
not rely on body to start the attack on the disease; instead, they use immune system components (such as 
antibodies) made in lab (Stites et al., 1994). The types of immunotherapy described in the following section 
include: T cell therapy, therapeutic antibodies, immunomodulation and plasmid DNA therapy (Har-Noy et al., 
2009).  
 
2.1. Cellular Therapy  
It is clear from observations of immune responses that some cells must be able to recognize foreign antigens and 
then respond to them (Tizard, 1996). Professional antigen presenting cells include Dendritic Cells (DCs), 
Macrophages, and B-cells. Of these DCs are the most potent antigen presenters given their morphologic and 
phenotypic properties (Igyarto and Kaplan, 2013). The response of these antigens – sensitive cells must act either 
in the production of antibodies or in the production of cells that can participate in the cell-mediated immune 
responses. Cells must also be generated that can respond even more effectively on second exposure to same 
antigen memory cells (Tizard, 1996).  
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2.1.1. Improving (stimulation) T cell therapy /Dendritic cell-based immunotherapy 
This novel approaches for increasing the efficacy of T cell therapy through genetic modification of specific T cells 
to improve their biological function (Rooney et al., 1998). The poor immunogenic of most tumor antigens largely 
reflects the non conductive context in which these antigens are naturally presented, as well as tolerance resulting 
from most tumor antigens being normal proteins aberrantly expressed by tumor. Therapeutic vaccines have 
attempted to evade these problems by presenting tumor antigens in a more enticing fashion, generally through 
activated dendritic cells (DCs). This has been achieved either by isolating DCs and introducing the antigen ex vivo 
before returning the DCs to the hosts, by inoculating dead tumor cells modified to secrete factors such as 
granulocyte-macrophage-colony stimulating factor (GM-CSF) that promote local accumulating of DCs, by 
injecting activators of DCs such as tumor like receptor (TLR) ligands or monoclonal antibodies (Mab) to CD40 
with the antigen, or by injecting recombinant vectors that provide both the antigen and a stimulus to the innate 
immune system (Waldman, 2005; Overes et al., 2009). Upon transfusion back into the patient these activated cells 
present tumour antigen to effector lymphocytes (CD4+ T cells, CD8+ T cells, and B cells). This initiates a 
cytotoxic response to occur against cells expressing tumour antigens against which the adaptive response has now 
been primed (Overes et al., 2009). The cancer vaccine Sipuleucel-T is one example of this approach (Di Lorenzo 
et al., 2011).  
2.1.1.1. Blockage of the actions of CTLA-4 and PD1 Inhibitory Receptors induced after cell activation  
Among the best studied of the immunological checkpoints is the cytokine T lymphocyte antigen – 4 (CTLA-4, 
CD152), a negative costimulatory molecule (Kwon et al., 1999; Rosenberg, 2004). The initial interaction of B7 
family members such as CD80 or CD86 with the CD28 costimulatory receptors provides a fundamental 
costimulatory signal that is required to initiate the T cell immune response, in addition to signaling that occurs 
through the T cell receptor for antigen. However, the expression of CTLA-4, a receptor that has a much higher 
affinity for B7 than CD28 is induced after T cell activation. CTLA-4 inhibits T cell activation and interleukins-
2(IL-2) production. Allison and coworker demonstrated that transient antibody-mediated blockade of B7-CTLA-4 
interaction enhanced the antitumor immunity provided by a GM-CSF transduced vaccine (Kwon et al., 1999). This 
coordinate strategy led to the regression of established transplanted syngeneic tumors and has induced remission in 
some patients with malignant melanoma (Waldmann, 2005).  
The immune system employs a series of checkpoints to protect normal, healthy tissue from an immune 
response. These consist of receptors on the surface of activated T cells and their corresponding ligands on the 
surface of antigen presenting cells. A key immune checkpoint is created when PD-1 (programmed cell death 
protein 1) engages its ligand PD-L1. As a result of this interaction, T cell activation is attenuated and an active 
immune response is prevented (Curran et al., 2010). This mechanism is also used by tumors. PD-L1 is 
upregulated in several tumor types and contributes to the malignancy of these cancers by interacting with PD-1 
and inhibiting T cell activation. In this way, the tumors avoid detection and destruction by the immune system. 
Accordingly, PD-1 and PD-L1 have garnered much attention for their roles in tumor immunology and as 
potential immune-based therapeutic targets. The interaction of PDl with programmed cell death ligand-l (PDL-1) 
or PDL2 dramatically inhibited T cell receptor mediated proliferation and cytokine secretion by CD 4+ T cells 
(Waldmann, 2005; Gameiro et al., 2014). 
2.1.1.2. Elimination of CD4 +CD25+ foxp 3 expressing Tregs (Regulatory T cell) 
Another immunological check point is mediated by Tregs that express CD4+ CD25+ fork head protein 3 (foxp3). 
These Tregs, or regulatory T cells, can compromise immune responses to tumor antigen (Randolph et al., 2006; 
Shevach, 2000). As is true of the other check points, CD4+ CD25+ Tregs are engaged in the control of self-
reactive T cells and there by contribute to the maintenance of immunological self tolerance.  In mice, 
administration of Pc61, a CD25 ( Interleukin-2 Receptor alpha/IL-2Rα) species Mab, led to the depletion of 
Tregs, which was associated with an augmented immune response to certain syngeneic tumors (Hurwitz et al., 
2000). In particular, Pc61 was associated with the induction of Cytotoxic T Lymphocytes (CTL) and Natural 
killer cell (NK- cell) mediated cytotoxicity that in turn led to tumor rejection. As noted above, CD25 is 
expressed not only by Tregs but also by activated effector T cells. Therefore, CD25 directed therapy to remove 
Tregs must preceded the administration of an antitumor vaccine that induces CD25 expression effector T cells. 
The triggering CTLA-4 blockade augments Tregs expression. However, anti- CTLA-4 therapy with an 
associated depletion of CD4+ CD25+ Tregs mediate by the simultaneous administration of Pc61 provided 
synergistic antitumor therapy in a murine B16 melanoma (Sutmuller et al., 2001).   
2.1.1.3. Targeting the Inhibitory Cytokine TGFβ  
Yet another mode of inhibition of cancer immunosurveillance is mediated by the CD4+, NK-T cell and 
production of IL-13. This induces the expression of Tumor necrosis factor-β (TGFβ) to inhibit the antitumor 
cytotocicity lymphocytes(CTL) mediated by CD8+ CTLs. Blockage of this negative regulatory pathway by 
inhibiting IL-13 action using an IL-13 receptor IgFc fusion protein enhanced antitumor responses and 
potentiated the efficacy of vaccines (Berzofsky et al., 2001). More broadly, as noted below, these checkpoints 
and others can be blockage using antibodies directed toward TGFβ (Gorelik et al., 2002). A number of 
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biologically active agents either synthesized directly by tumor cells or secreted by host cell in association with 
tumor growth exert suppressive effects on the immune system (Gorelik et al., 2001). As just noted, TGFβ is one 
of the most prominent. It is produced not only in association with the CD4+ NK-Tell and IL-13 system but also 
in association with the actions of Tregs, NK cells, macrophage, epithelial cells, and stromal cells (Gorelik et al., 
2002).  
TGFβ is a pleiotropic cytokine that inhibits T cell proliferations and differentiation into CTLs and 
helper cells, and thereby prevents an effective immune response to the tumor. TGFβ is produced not only by host 
cells but by a wide array of tumor tissues. Such TGFβ production can have an important role in the suppression 
of antitumor immune response. Gorelik and Flavel utilized CD8 T cell genetically altered so that they could not 
respond to TGFβ, to demonstrate that T cells specific blockade of TGFβ signaling allows the generation of tumor 
specific CTL responses (Gorelik et al., 2002). Such T cells were able to eradicate tumors in mice challenged 
with melanoma tumor cells. Thus, the use of Mabs or TGFβ-RII- directed blockade of TGFβ action on T cell 
signaling could be translated to clinical situations to improve existent cell-mediate antitumor immunity (Gorelik 
et al., 2001).  
Table 1: Blockage of immunoregulatory negative checkpoints that impede immunotherapy 
Host negative immunoregulatory mechanism      Potential intervention to release 
Checkpoint on the immune response                                                                                     
Signal mediated by negative T cell  
costimulatory molecule CTLA-4 after interaction with CD80,86 
family on APCs deliver signals that terminate T cell activation 
Antibody-mediated blockage of CTLA-4  
to enhance antitumor immunity induced 
by vaccine 
PD1 interaction with PDL1 or PDL2 inhibits 
T cell receptor –mediated proliferation  
and activation  of CD4 + T cells 
Anti-PDL1 antibody 
CD4+CD25+ negative regulatory Tregs  
(suppressor T cells ) inhibit antitumor 
 immune  responses                                      
Oncotoxin (IL-2 diphtheria toxin, 
anti-2Rα pseudomonas toxin. orCD25-
directed  
antibody (PC61) therapy to deplete Tregs 
CD4+ NK T cell generation of IL-13 that                   
Indirectly (through the action of TGFβ) inhibit                
 CD8+ cell-mediate antitumor responses. TGFβ  
is also synthesized directly b tumor cells or 
by host cells via other mechanisms    
IL-13Ra IgFc or anti-TGFβ       
monoclonal antibody  
 
Source: Waldmann, 2005 
2.1.2. Adoptive cell therapy   
Transplantation of immunocomptent cells from normal donor or patient with cancer is the method used to achieve 
immune function in immune deficient diseases and tumor. Adoptive cell therapy approaches to date have used 
tumors, peripheral blood malignant effusion, and draining lymph node as the anatomic source of input T cells for 
adoptive transfer. However, mainly using of CD8+ T cell for adoptive therapy as opposed to other cytolytic cells 
such as natural killer cell is their ability to specifically target cells through the recognition of differentially 
expressed proteins presented on the surface. Using T cell for adoptive therapy is also attractive due to the long 
clonal life spans of T cells which allow both therapeutic and immunoprophylactic scenarios to be envisioned. In 
addition T cells are well suited for genetic manipulation and its safe, effective and protective in vivo (June, 2007).  
An alternative to using allogeneic T cells to mediate antitumor responses has been to isolate autologous 
tumor- reactive T cells, expand the cells in vitro, and then reinfuse the cells back into the patient. Analogous 
adoptive therapy trials for immunosupressed hosts have demonstrated increased in vivo proliferation and 
persistence of CD8 effector T cells in the presence of specific CD4+ helper cells. Such CD4+ T cells likely 
provide many beneficial functions including cytokine production and APC activation which can improve the 
quality and quantity of the CD8+ responses, as well as direct effector activities against infected or tumor targets. 
Consequently, the largest experience is with IL-2 which clearly prolongs persistence and enhances the antitumor 
activity of transferred CD8+ cells (Riddle, 1995). Alternative cytokines such as IL-15, IL-7, and IL-21 as well as 
activations of APCs with antibodies to CD40 are currently being evaluated in clinic. The transfer of antigen 
specific CD8+ T cell clones has been shown to be effective for prevention of viral infections and treatments of 
malignant diseases (Salvin, 2001). 
 
2.2. Therapeutic Antibodies  
Therapeutic antibodies are lab engineered substances that recognize and bind onto a protein on the surface of cell. 
Each therapeutic antibody recognizes different protein or antigen, and in general can be used alone, in combination 
with chemotherapy or as carrier of substance such as toxins or radiation. After being to the targeted site, the 
therapeutic antibody can block the growth of tumor and/or recruit body’s immune system to attack the target, and 
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can also sensitize a cancer cell to chemotherapy (Tizard, 1996).   
2.2.1. Monoclonal antibodies 
Monoclonal antibodies are monospecific antibodies that are made in laboratory from a single clone of B cell. 
These proteins are designed to attach to area on the surface of pathogenic agents and interfere with their growth 
and spread. Once the antibodies are given, they can then recruit other parts of the immune system to destroy the 
cancer cells. Two types of monoclonal antibodies are used in cancer treatments (Witzig, 2002). 
2.2.1.1. Naked monoclonal antibodies  
Naked Mabs are the most commonly used Mabs at this time. Although they all work by attaching themselves to 
specific antigens, they can be helpful in different ways. 
i) Markers for destruction  
Some naked Mabs attach to cancer cells to act as a marker for the body's immune system to destroy them. 
Antibodies now in use in this group include: Rituximab (Rituxan), Ofatumumab, Alemtuzumab (Campath) 
( Witzig, 2002).  
ii) Activation blockers  
Some naked Mabs don't really interact with a person's own immune system. Their effects come from their ability 
to attach to the specific antigens that are working parts of cancer cells or other cells that help cancer cells grow, 
and stop them from working. These Mabs are also referred to as targeted therapies. Examples of FDA-approved 
Mabs of this type include: Cetuximab (Erbitux), Trastuzumab (Herceptin) for cancer (Waldmann, 2005).  
2.2.1.2. Conjugated monoclonal antibodies  
Conjugated Mabs are monoclonal antibodies that are attached to drugs, toxins, or radioactive substances. The 
Mabs are used as homing devices to take these substances directly to the cancer cells. The Mab circulates in the 
body until it can find and hook onto the target antigen. It then delivers the toxic substance where it is needed most. 
This lessens the damage to normal cells in other parts of the body (Denny, 2004).  
Conjugated antibodies may pack more of a punch than naked Mabs, but for this reason they often cause more side 
effects, too. The side effects depend on which type of substance they're attached to. For example, Ibritumomab 
tiuxetan (Zevalin) delivers radioactivity directly to cancerous B lymphocytes. It is used to treat B-cell non-
Hodgkin lymphoma that has not responded to standard treatment (Waldmann, 2003). 
Strategies and Targets of Monoclonal Antibody Action  
A diverse array of strategies and cellular targets of antibody action have been employed in patient with cancer. 
Cellular targets include the tumor cells themselves, tumor vasculature, and various host-negative 
immunoregulatory elements (check points). The mechanism of action antibodies directed toward the tumor cells 
themselves include: One mechanism of action is a direct cytotocic action on the tumor cells mediated by the Mabs. 
For example, CD30-directed Mabs facilitate a target cell’s death-signaling path -way rather than the cell-
proliferation pathway mediated constitutively by the tumor necrosis factor-α (TNFα) receptor. By eliminating the 
proliferation and survival path way, the antibody kills CD30-expressing anaplastic large cell lymphoma cells (Mir 
et al, 2000). 
A second mechanism is antibody-dependent cellular cytotoxicity (ADCC) mediated target- cell killing – 
a process that involves the redirection of host cytotoxic mononuclear cells to the tumor. Clynes et al., (2000) 
demonstrated that antibody engagement of receptors utilizing the FcRγ subunit plays a major role in the tumor-
cell effector function of select Mabs in murine xenogeneic models of human malignancy. They showed that the 
efficacy of antibodies directed toward malignant melanoma cells was greatly diminished (Clynes et al., 2000). 
A third strategy is to use cytokines (e.g., IL-2, IL-4, IL-12, and GM-CSF) genetically linked to Mabs to 
induce NK cell and T cell proliferation at the tumor site (Lode et al, 2000). A fourth is to the antigen specifically 
of the Mabs to deliver cytocidal agents to the surface of the tumor cell (Witzig et al., 2002). For example, 
pretargeting strategies have been used to for the selective delivery of enzymes that activate prodrugs within the 
tumor, thereby diminishing the toxicities of the active drug through administer antibody-dependent enzyme-
mediated prodrug therapy (ADEPT), an antibody-fragment-enzyme fusion protein is allowed to localize in the 
tumor. After the fusion protein is cleared from the circulation, the prodrug is administered and converted to an 
active drug by the enzyme focused within the tumor (Denny, 2004).  
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Table 2.  Monoclonal antibodies for cancer treatment. 
Year 
approved 
Brand name Generic name Type of mAb Target Indication  
1997  
 
1998  
 
2000  
 
2001  
 
2002  
 
2003 
 
2004 
 
2006 
Rituxan  
 
Herception  
 
Mylotarg  
 
Campath-I  
 
Zevalin  
 
Avastin  
 
 Erbituxx  
 
Vectibix® 
Rithximab  
 
Trastuzumab  
 
Gemtuzumab 
Ozogamicin  
Alemtuzumab  
 
Ibritumomab 
Tiuxetran  
Tositumomab 
 
Bevacizuma 
Cetuximab  
Panitumumab   
Chimeric  
 
Humanized  
 
Humanized  
 
Humanized  
 
Murine  
Radiolabeld  
Murine 
Radiolabeled  
Humanized  
Chimeric  
Radiolabeled 
CD-20 
 
HER-2 
 
CD-33 
 
CD-52 
 
 
CD-20  
CD-20  
 
VEGF  
EGFR 
(HER1)  
Non-Hodgkin’s  lymphoma  
HER-2/neu positive 
 metastatic breast cancer  
 
Acute   myelogenous leukemia  
 
B-cell chronic lymphocytic leukemia  
 
 
Non-Hodgkin’s lymphoma  
Non-Hodgkin’s lymphoma  
 
Colorectal cancer 
Colorectal cancer 
 Colorectal cancer  
2004 
 
Erbitux®  Cetuximab Chimeric EGFR 
(HER-1 
Colorectal cancer  
head & neck cancers  
2006 Avastin®  Bevacizumab  Humanized  Breast  & kidney cancer 
2009 Arzerra®  Ofatumumab Radiolabeled  chronic lymphocytic LL) 
Key: VEGF  Vascular endothelial growth factor 
Source: Hay-Novy (2009) and Waldman (2005) 
2.2.2. Polyclonal antibody 
Polyclonal antibodies are antibodies that are derived from many different B cells or B cell lines, similar to the 
mixture of antibodies found in sera. Polyclonal antibodies are therefore a mixture of much different specificity. 
This is in contrast to monoclonal antibodies which are derived from one clone. Immunization may be 
accomplished passively by administering either performed immune active serum or cell (CDC, 2009). 
Antibody, either as whole serum or as fractionated, concreted immune globulin that is predominantly 
IgG, may be obtained from human or animal donors who have recovered from an infectious disease or have been 
immunized. These antibodies may provide immediate protection to antibody-deficient individual. Passive 
immunization is thus useful for individuals who cannot form antibodies or for the nonimmunocompromised host 
who might develop disease before active immunization could stimulate antibody production, which usually 
requires at least 7-10 days (Stites et al., 1994). 
Additionally, passive immunization is useful when no active immunization is available, when passive 
immunization is used in conjunction with vaccine administration (e.g. in rabies vaccination), in the augment of 
specific effects of certain toxins and venom, and, finally, as immunosuppressant. Antibody may be obtained 
from humans or animals sera give rise it an immune response that leads to rapid clearance of the protective 
molecules from the circulation of the recipient and the risk of allergic reaction, particularly serum sickness or 
anaphylaxis. Thus, to obtain similar protective effect, much more animal antiserum must be injected compared 
with human antiserum (Stites et al., 1994). 
 
2.3. Immunomodulatory Strategies  
Immunomodulators are biology response modifying compound that affect the immune response in either a positive 
or negative fashion. There are many ways in which the cytokine network might be exploited therapeutically, 
whether positively by cytokine administration or negatively by inhibition or by more suitable modulation through 
therapeutic intervention in the cytokine network (Kelso, 1998). 
2.3.1. Inhibition (Elimination) of endogenous cytokine production or action 
This action is achieved using neutralizing antibodies against soluble cytokine receptors, antisense oligonucletides, 
pharmacologic inhibitors of signal transduction, natural and synthetic receptor antagonists permanently by gene 
inactivation as a result of natural mutation or generating in embryonic stem cells (Walker, 1999). For example, IL-
4 and IL-5 where both transient neutralization and gene targeting have confirmed the key selective role of these 
cytokines in IgE synthesis and  eosinophilia respectively, in the immune response to air way allergens and gut 
nematodes. In these examples the consistency of outcome of the two approaches to cytokine elimination reflects 
the fact that IgE synthesis and eosionophilia are induced responses to infection or allergenic change (Weiner, 
1997).  
2.3.2. Stimulation or modulation of endogenous cytokine production  
 Different immunogen induce the synthesis of different cytokines which in turn activated different immune 
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effector mechanisms. These include a large number of compounds, which can be divided into 3 broad categories 
(Stites et al., 1994). 
2.3.2.1. General immunostimulatory agents  
These are mostly of bacterial origin such as BCG (attenuated mycobacterium bacillus calmatte Guerin). BCG 
stimulates macrophage, T and B lymphocyte, and natural killer (NK) cells function and to augment interleukin 1 
(IL-1) production. An injection of BCG into lesion of malignant melanoma has led to remission of the local tumor 
as well as distant metastases (Chirigos, 1992).  
2.3.2.2. Eukaryotic source substance 
 Especially we focus on cytokines. The term cytokine define a large group of non enzyme protein hormones whose 
actions are both diverse and overlapping and which affect diverse and overlapping target cell population. They are 
generally subdivided into four groups (Stites et al., 1994). 
i) Interferons   
Although interferons (IFNs) were first recognized for their effect on viral infections, their clinical usefulness as 
immunomodulators has been demonstrated in certain neoplastic diseases (e.g. leukemia lymphoma) as well. For 
example IFNα, natural product of macrophage, has demonstrated antitumor activity in a numbers of neoplastic 
disorders. Also, IFNγ, a product of lymphocytes has extensive activity in a variety of tumors and viral infections 
(Rees, 1992).      
ii) Haemopoietic colony- stimulation factors  
They are erythropoietin, now used routinely to treat anemia in patients with chronic renal disease, granulocyte 
colony stimulating factor (G-CSF), macrophage, colony-stimulating factor (M-CSF), and granulocyte macrophage 
colony stimulating factor (GM – CSF) (Blackwell et al., 1992).  
iii) Growth and differentiation factors  
Perhaps the best studied growth and differentiation factor is transforming factor beta (TGFβ), which has a wide 
range of effect on the immune response. It has potential benefit as an accelerator of wound healing, and markedly 
inhibits the IL-4 stimulated synthesis of IgE and may be clinically useful as an antiallergy drug (Stites at el., 1994). 
iv)  Interleukins (ILs) 
Interleukins are a diverse group of cytokines exhibiting a broad array of actions on the immune system. These 
have potential usefulness as therapeutic immunomodulators. For instance, Interleukin 2 (IL-2) has been used 
successfully in the treatment of certain tumor (such as malignant melanoma, renal cell carcinoma). This is 
possibility due to activation and proliferation of lymphocyte activated killer cells (LAK) derived from the patient 
peripheral blood leukocytes. Recently, IL-2 has been used to productive ex vivo activation of a subset of 
lymphocytes derived from soidtumors, known as tumor- infiltrating lymphocytes (TIL) (Thompson,1992).  
Tumor necrosis factor (TNF), a cytokine that has antitumor activity both in vitro and in vivo through: 
directly slowing the growth of cancer cells, slowing down angiogenesis, the growth of new blood vessels that 
tumors must have in order to grow, causing cancer cells to produce more antigens, making them easier for the 
immune system to see and destroy, boosting the cancer cell-killing ability of natural killer (NK) cells and of 
other immune system cells that attack cancer with help from antibodies( Prehn,1996).  
2.3.2.3. Biochemical agents 
They act via their ability to induce the production of interferons (Amery, 1992). For instance, the best known 
biochemical immunoimodulator is levamisole, an imidathiazole compound originally studied for its anthelmintic 
activity. It is immunotrophic; however, its mechanism of function is unknown and it exhibits no direct cytotoxic 
activity. It has little effect in immunocompetent individuals it has been shown to reverse post viral energy 
associated with measles and influenza and has some benefit in chronic infections, and neoplastic diseases (Amery, 
1992).  
 
2.4. Plasmid DNA therapy 
Plasmids are autonomously replicating entities which can be found essentially in all bacterial species and which 
play a significant role in bacterial adaptation and evolution. Furthermore, plasmids are studied for their own sake 
and serve as important tools in studies of molecular biology (Summer, 1996). Plasmids are normally circular, 
although linear forms have also been described, and vary widely in size from 1 kb to 200 kb. Larger plasmids of 
up to 1000 kb, termed mega plasmids, have also been identified. The copy number per chromosome also varies 
among plasmids, and bacterial cells can carry more than one type. Like chromosomes, plasmids code for RNA 
molecules and proteins, replicate as the cell grows, and equal numbers are normally distributed to the two daughter 
cells upon cell division. However, plasmids do not code for functions which are essential to bacterial growth in the 
absence of any stressful situation, e. g., in the absence of an antibiotic (Schorr et al., 1996). 
The experimental work on DNA vaccines in preclinical animal models explores its potential for 
prophylaxis and therapy in four areas that are of interest in human and veterinary medicine. These comprise the 
following: control of infectious disease, immune therapy of cancer, specific treatment of autoimmune disease, 
immunmodulation of allergic disease (Schneide et al., 1998).  
Journal of Health, Medicine and Nursing                                                                                                                                          www.iiste.org 
ISSN 2422-8419     An International Peer-reviewed Journal 
Vol.19, 2015 
 
83 
 
For example, consider allergy treatment. Immune reactions underlying allergy are characterized by a 
strong Th2 phenotype, and DNA vaccination often introduces a strong Thl-bias into the immune responses it 
primes or boosts. In mouse models, allergy-inducing Th2 responses have been converted into non-pathogenic 
Thl responses against the allergen by DNA vaccination (Schneide et al., 1998; Ziegelhof et al., 1997; Schorr et 
al., 1996). The inhibition of IgE antibody formation by plasmid DNA immunization has been shown to be 
mediated by both CD4+ and CD8+ T cells (Lee et al., 1997). DNA vaccination is an exceptionally potent 
strategy to stimulate T cell responses. This makes DNA-based immunization an interesting strategy for 
vaccination against intracellular pathogens and cancer. Different mechanisms seem to be involved in priming T 
cells by genetic vaccination (Schorr et al., 1996). Also immunomodulatory roles of plasmid DNA is mediated 
through the following mechanisms: potent inducer of protective anti-viral CTL responses; override non- or low 
responder status in anti-viral T cell reactivity; overcome low responsiveness or tolerance induction in neonatal 
immune system convey cross-strain protection against viruses and support priming of anti-viral CTL despite 
deficient CD4’ T cell helper activity (Schneide et al., 1998). 
 
3. APPLICATION OF IMMUNOTHERAPY  
Most of immunotherapy is ideal treatment but some strategies are practical applied (Morgan, 2004).  
 
3.1. Viral therapy  
In persistent virus infections where viral replication is controlled by specific CTL such as Epstein Barr Viruses 
(EBV) and cytomegalovirus (CMV), adaptive transfer of CTL generated from the origin marrow donor to patients 
immunosuppressed following allogeneic SCT had prove beneficial in reducing the incidence of serious viral 
disease (Roony et al., 1998).  
 
3.2. Cancer Therapy  
Cancer immunotherapy attempts to stimulate the immune system to reject and destroy tumors. Immuno cell 
therapy for cancer was first introduced by Rosenberg and his colleagues of the National Institutes of Health in the 
United States in the late 1980s. They reported a low tumor regression rate (2.6–3.3%) in 1205 patients with 
metastatic cancer who underwent different types of active specific immunotherapy (ASI), and suggested that 
immuno cell therapy along with specific chemotherapy is the future of cancer immunotherapy(Rosenberg,1984). 
Initially Immunotherapy treatments involved administration of cytokines such as Interleukin. Thereafter the 
adverse effects of such intravenously administered cytokines lead to the extraction of the lymphocytes from the 
blood and expanding in vitro against tumour antigen before injecting the cells with appropriate stimulatory 
cytokines. The cells will then specifically target and destroy the tumor expressing antigen against which they have 
been raised (Yang et al., 2003; Egawa et al., 2004; Li et al., 2005). T Lymphocytes play a key role in maintaining 
antitumor immunity and provide an important opportunity for the immunotherapy of cancer. For example, transfer 
of T lymphocytes with antitumor activity via tumor infiltrating lymphocytes (TILs). There are lymphocytes that 
have been obtained from tumor tissue by mechanical means and enzymatic digestion of tumor specimens. A 
single-cell suspension is then cultured for several weeks before TILS can be harvested. TLIS cultured in the 
presence of IL-2 produce cytotoxic effects in colon carcinoma melanoma, and bladder carcinoma (Dudley, 2000).  
 
3.3. Allergy Desensitization Therapy  
Immunotherapy is also used to treat allergies. While other allergy treatments (such as antihistamines or 
corticosteroids) treat only the symptoms of allergic disease, immunotherapy is the only available treatment that 
can modify the natural course of the allergic disease, by reducing sensitivity to allergens. Immunotherapy does 
not work for everyone and is only partly effective in some people. The therapy is indicated for people who are 
extremely allergic or who cannot avoid specific allergens. For example, they may not be able to live a normal 
life and completely avoid pollen, dust mites, mold spores, pet dander, insect venom, and certain other common 
triggers of allergic reactions. Immunotherapy is generally not indicated for food or medicinal allergies. This 
therapy is particularly useful for people with allergic rhinitis or asthma (Durham et al., 1999). 
The therapy is particularly likely to be successful if it begins early in life or soon after the allergy 
develops for the first time. Immunotherapy involves a series of injections (shots) given regularly for several 
years by a specialist /allergists. The first shots contain very tiny amounts of the allergen or antigen to which one 
is allergic. With progressively increasing dosages over time, one's body adjusts to the allergen and becomes less 
sensitive to it, in a process known as desensitization.  In many allergic diseases may be controlled through the 
use of “allergy shots”. It was originally believed that injection of the allergen stimulate the production of IgG 
antibodies. It was anticipated that these would compete with IgE for antigen and, therefore, prevent the antigen 
from reaching the mast cells. Although partially correct, it is also probable that allergy shots stimulate Th1 cells 
to release IFNγ. This IFNγ blocking stimulation of IgE antibody synthesis by IL-4 from Th2 cells (Stites at el., 
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1994). 
 
Figure 1: Allergy Desensitization Therapy  
Source: Stites at el., 1994 
 
4. CHALLENGES OF IMMUNOTHERAPY 
Immunotherapeutic have risks that are, at this early stage of development of the novel vaccination technique, 
difficult to assess critically. The limited experience with safety considerations obtained in animal models suggests 
the following potential risks (Waldman, 2003). 
 
4.1. Toxicity  
One major difficulty in cytokine therapy has been toxicity. For example, TNF produces clinical signs similar to 
those induced by endotoxin. IL-2 and IL-4 are extremely toxic when administered alone. In low doses it induces 
fever, chills, nausea, and anemia, thrombocytopenia and eosinophilia. Patients may develop a severe, very itchy 
rash and endocrine abnormalities (Michilak at el., 2004). 
 
4.2. Hypersensitivity  
An IgE response is a potential hazard that may result from the administration of any antigen, including vaccine. 
The term hypersensitivity is used to denote a severe reaction that occurs in response to normally harmless 
materials. For instance, normal animal do react to antigen then activated immunoresponse to release histamine and 
prostaglandin (Tizard, 1996).  
 
4.3. Graft-versus Host Rejection 
If healthy lymphocytes are injected into the skin of an allogeneic recipient, the lymphocyte attach the host cells 
leading to a local acute inflammatory response provided the recipient has a functioning immune system This graft-
versus-host (GVH) reaction is not serious, since the recipient is able to destroy the foreign Lymphocytes and thus 
terminate the reaction.  However, the recipient cannot reject the graft Lymphocyte because it has been 
immunosuppressed or immunodeficient, these cells may cause uncontrolled destruction of the host’s tissues and 
eventually death (Tizard, 1996).     
 
4.4. Mutation  
Another problem of immunotherapy is emergence virus escape mutants are major concern during viral replication 
will lead to resistance to antiviral drug (Fung et al., 2006). For example, activation of B cell by HCV envelope 
protein (E2) CD81 is through to be a cellular receptor for HCV based on its ability to bind E2 (Zham et al., 2004). 
Binding of CD81 with E2 or certain Mab against CD81 induces B cell aggregation; inhibit NK cell functions 
(Crotta et al., 2002).  
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5. CONCLUSION AND RECOMMENDATIONS  
The best way to prevent and remove infections is through the natural 'sterilizing' action of the immune response 
that combines elements of both innate and adaptive immunity to ward off foreign pathogens without medical 
intervention. Innovation in immunology in the form of prophylactic and therapeutic vaccines has been used to 
treat a variety of infectious and non infectious disease. Immunotherapy is a highly desirable alternative to current 
treatment strategies than surgery, radiation and chemotherapy due to well suited for genetic manipulation and its 
safe, effective and protective in vivo with low toxicity and a durable treatment response. Two main types of 
immunotherapy strategies are passive and active. But most of them are ideal treatment and some strategies are 
practical like cancer therapy and allergic desensitization. Among the risk immunotherapeutic strategies are 
toxicity, hypersensitivity, graft-versus host rejection, and Mutation are the major one. In the light of the above 
conclusive remakers the following point are recommended: further studies should be carried out on desirable and 
side effects of immunotherapeutic and Technology should be refined in a way to minimize well-being and 
ethical concerns. 
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